Ximelagatran versus warfarin: A comparison of bleeding outcomes in patients with nonvalvular atrial fibrillation

被引：0
|
作者：
Douketis, JD
Arneklev, K
Goldhaber, S
Spandorfer, J
Halperin, F
Horrow, J
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] AstraZeneca R&D Molndal, Biostat, Molndal, Sweden
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
[5] Kelowna Gen Hosp, Kelowna, BC, Canada
[6] AstraZeneca LP, Wilmington, DE USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.1765.1765
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1765
引用
收藏
页码：489A / 489A
页数：1
相关论文
共 50 条
  • [41] Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin
    Datar, Manasi
    Crivera, Concetta
    Rozjabek, Heather
    Abbass, Ibrahim M.
    Xu, Yihua
    Pasquale, Margaret K.
    Schein, Jeff R.
    Andrews, George A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (05) : 275 - 285
  • [42] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [43] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
  • [44] Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Peripheral Artery Disease
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    [J]. STROKE, 2018, 49
  • [45] Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation
    Piccini, Jonathan P.
    Hellkamp, Anne S.
    Washam, Jeffrey B.
    Becker, Richard C.
    Breithardt, Guenter
    Berkowitz, Scott D.
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Hacke, Werner
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Singer, Daniel E.
    Fox, Keith A. A.
    Patel, Manesh R.
    [J]. CIRCULATION, 2016, 133 (04) : 352 - 360
  • [46] Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
    Mark J. Alberts
    Jinghua He
    Akshay Kharat
    Veronica Ashton
    [J]. American Journal of Cardiovascular Drugs, 2022, 22 : 425 - 436
  • [47] Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
    Alberts, Mark J.
    He, Jinghua
    Kharat, Akshay
    Ashton, Veronica
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (04) : 425 - 436
  • [48] Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation
    Tamura, Akira
    Yamamoto, Ena
    Kawano, Yoshiyuki
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2020, 136 : 71 - 75
  • [49] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
    Weir, Matthew R.
    Chen, Yen-Wen
    He, Jinghua
    Bookhart, Brahim
    Campbell, Alicia
    Ashton, Veronica
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (11)
  • [50] Rivaroxaban versus Warfarin: Effect on Healthcare Resource Utilization and Costs in Nonvalvular Atrial Fibrillation Patients
    Laliberte, Francois
    Crivera, Concetta
    Nelson, Winnie W.
    Olson, William H.
    Schein, Jeffrey
    Germain, Guillaume
    Lefebvre, Patrick
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 480 - 481
12345